Number of PML diseases under Tysabri (June 2016)

As of September 7, 2016, there have been 685 (683 MS, 3 CD) confirmed PML cases worldwide.
As of August 31, 2016, overall PML incidence: 4.22 per 1000 patients (95% CI 3.91 to 4.55 per 1000 patients). 23% of patients have died; 77% of patients are alive with varying levels of disability.
As of June 30, 2016, approximately 156,500 patients received natalizumab in post-marketing setting worldwide.

After the re-approval of Tysabri® (Natalizumab), there were the expected/feared PML disorders. I have generated a table with the main available data from June 2008 to june 2016.

I would be grateful for additional information via comment or e-mail. Tysabri®, Avonex®, Rebif® & Copaxone® are trademarks.

Alexander Otto
… back to the myelounge (german) »

Disclaimer

200 Gedanken zu „Number of PML diseases under Tysabri (June 2016)

  1. Alexander Otto Beitragsautor

    Bad news again:

    As of June 3, 2016, there have been 667 (664 MS, 3 CD) confirmed PML cases worldwide.

    As of May 30, 2016, overall PML incidence: 4.22 per 1000 patients (95% CI 3.91 to 4.55
    per 1000 patients). 23% of patients have died; 77% of patients are alive with varying levels of disability.

    As of March 31, 2016, approximately 152,500 patients received natalizumab in post-marketing setting worldwide.

  2. Alexander Otto Beitragsautor

    Bad news again:
    As of October 1, 2013, there have been 410 (408 MS, 2 CD) confirmed cases of PML worldwide.
    23% of the patients with PML have died; the patients who are alive have varying levels of disability, ranging from severe to moderate to mild. PML usually leads to death or severe disability.
    As of October 1, 2013, the overall incidence of PML in natalizumab-treated patients is 3.36 per 1000 patients (95% CI 3.04 to 3.70 per 1000 patients).
    As of June 30, 2013, approximately 118,100 patients received natalizumab in post-marketing setting worldwide.

Schreibe einen Kommentar